Pharmacokinetic-pharmacodynamic modeling and simulation:concepts and basic principles(2)

Abstract

Abstract: Modeling and simulation (M&S) is an important research field in pharmacokinetics and pharmacodynamics.M&S has evolved from a tool primarily applied to therapeutic drug monitoring to one that plays a significant role in drug development.Technological advances in various fields related to drug development call for more focus on ways to optimize current drug development practices.Recognition of the potential of M&S by regulatory agencies inevitably has a substantial impact on drug development.The objective of the current review is to present the some basic concepts and principles of M&S. Some case studies are presented to illustrate how M&S can facilitate knowledge management and decision making.In this article the model development process and goodness of fit criteria were discussed.

Key words: pharmacokinetics, pharmacodynamics, mathematical model, modeling and simulation, goodness of fit

CLC Number:

R911

HUANG Xiao-hui, SHI Jun, LI Jun, SONG Guo-qiang, XIE Hai-tang, ZHENG Qing-shan, SUN Ruiyuan. Pharmacokinetic-pharmacodynamic modeling and simulation:concepts and basic principles(2)[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 334-341.

References

1 Bonate PL.Pharmacokinetic-pharmacodynamic modeling and simulation[M].New York:Springer, 2005:10-19.
2 Chatfield C.Problem solving-A statistician' s guide[M].London:Chapman and Hall, 1988.
3 黄晓晖, 史军, 李俊, 等.药代动力学与药效动力学中数学建模与模拟的基本原理(1)[J].中国临床药理学与治疗学, 2007;12:82-89.
4 Gobburu JV, Tammara V, Lesko L, et al.Pharmacokineticpharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer' s disease[J].J Clin Pharmacol, 2001;41:1082-1090.
5 Longnecker SM, Donehower RC, Cates AE, et al.High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial[J].Cancer Treat Rep, 1987;71:53-59.
6 Wiernik PH, Schwartz EL, Strauman JJ, et al.Phase I clinical and pharmacokinetic study of taxol[J].Cancer Res, 1987;47: 2486-2493.
7 Huizing MT, Keung AC, Rosing H, et al.Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients[J].J Clin Oncol, 1993;11:2127-2135.
8 Gianni L, Kearns CM, Giani A, et al.Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic pharmacodynamic/relationships in humans[J].J Clin Oncol, 1995;13:180-190.
9 Brown T, Havlink, Weiss G, et al.A phase I trial of taxol given by a 6-hour intravenous infusion[J].J Clin Oncol, 1991;9: 1261.
10 Eisenhauer EA, ten Blokkel Huinink WW, Swenerton KD, et al.European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer:high-dose versus low-dose and long versus short infusion[J].J Clin Oncol, 1994;12:2654-2666.
11 Sonnichsen DS, Relling MV.Clinical pharmacokinetics of paclitaxel[J].Clin Pharmacokinet, 1994;27:256-269.
12 Sparreboom A, van Zuy len L, Brouwer E, et al.Cremophor EL-mediated alteration of paclitaxel distribution in human blood:clinical pharmacokinetic implications[J].Cancer Res, 1999;59:1454-1457.
13 Karlsson MO, Molnar V, Freijs A, et al.Pharmacokinetic models for the saturable distribution of paclitaxel[J].Drug Metab Dispos, 1999;27:1220-1223.
14 Pan H, Cole TJ.A comparison of goodness of fit tests for agerelated reference ranges[J].Stat Med, 2004;23:1749-1765.
15 Bentler PM, Bonnett DG.Significance tests and goodness of fit in the analysis of covariance structures[J].Psychological Bulletin, 1980;88:588-606.
16 Hill AB.The environment and disease:association or causation [J].Proc R Soc Med, 1965;58:295-300.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[4]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[5]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[6]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[7]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[8]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[9]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[10]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[11]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[12]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[13]	GU Yifei, CHU Nannan, HUANG Kai, QUE Linling, ZHANG Jisheng, XIANG Xuemei, HE Qing. Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 822-833.
[14]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
[15]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.